News | December 12, 2022
Lupin launches generic version of Pennsaid in the US
Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of US $509 million in the US (IQVIA MAT October 2022)
Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of US $509 million in the US (IQVIA MAT October 2022)
Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business
More women centric initiatives being the need of the hour for holistic development
The use of procalcitonin testing for sepsis management is highest in the US
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Total investment envisaged in this project stands at up to Rs 70 crore
Government of India has granted a patent for invention entitled "An improved safe process for the preparation of Sartan drugs of Formula I".
Subscribe To Our Newsletter & Stay Updated
